Autres langues Clearside Biomedical, Inc.

Actions

CLSD

US1850631045

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,34 ^USD	+6,35%		+2,29%	+14,53%

16/04	Clearside Biomedical, Inc. nomme Anthony S. Gibney à son conseil d'administration	CI
18/03	Clearside Biomedical nomme Victor Chong directeur médical	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors	16/04
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	16/04
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Clearside Biomedical Names Victor Chong Chief Medical Officer	18/03
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18/03
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18/03
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024	29/02
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering	07/02
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO	22/01
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14/12
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14/12
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update	13/11
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference	08/11
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting	07/11
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	03/11
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clearside Biomedical, Inc.

Actions

CLSD

US1850631045

Autres langues

Filtres